Zhitong Finance App News, Fosun Pharmaceutical (02196) announced that on April 9, 2024, the company's holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. (“Fuhong Hanlin”) and its holding subsidiaries Shanghai Fuhong Hanlin Biopharmaceutical Co., Ltd. (“Hanlin Pharmaceuticals”), Shanghai Fuhong Hanlin Biomedical Co., Ltd. (“Hanlin Pharmaceutical”) and China Merchants Bank Co., Ltd. Shanghai Branch (“China Merchants Bank”) signed a “Credit Agreement”. Fu Hong Hanlin (as credit applicants), Hanlin Pharmaceuticals, and Hanlin Pharmaceuticals (as credit applicants) signed a “Credit Agreement”. (Letter sharing applicant) Joint investment promotion The principal amount applied for by the bank shall not exceed the shared credit line equivalent to RMB 200 million (the credit applicant and the credit sharing applicant have financed with China Merchants Bank before the agreement is signed and the balance of the unpaid debt is included and occupied by the credit line). The credit period starts on April 10, 2024 and ends on April 9, 2025 (including the first and last two days). On the same day, Fuhong Hanlin issued a “Maximum Irrevocable Guarantee” (hereinafter referred to as “Guarantee Contract 1”) to China Merchants Bank. Fuhong Hanlin provided the maximum amount of joint liability guarantees for Hanlin Pharmaceutical and Hanlin Pharmaceutical's application to China Merchants Bank within the above amounts, not exceeding the equivalent of RMB 100 million and RMB 50 million of shared credit lines.

On April 9, 2024, the holding subsidiary Fuhong Hanlin signed a “Maximum Principal Guarantee Contract” (hereinafter referred to as “Guarantee Contract 2”) with China Construction Bank Corporation Shanghai Xuhui Branch. Fuhong Hanlin will provide its holding subsidiary Hanlin Pharmaceuticals (1) debts that have been funded by China Construction Bank and have not yet been paid (such surviving debts are automatically included in the principal amount of the financing debt), and (2) between February 2, 2024 and March 31, 2025 (including the first and last two days) of the maximum liability guarantee for debts under the main financing contract signed with CCB guarantee, The total principal amount of these financing debts does not exceed RMB 150 million.

On April 9, 2024, the holding subsidiary Fuhong Hanlin and the Changning Branch of Shanghai Pudong Development Bank Co., Ltd. (hereinafter referred to as “SPD Bank”) signed the “Maximum Guarantee Contract” (hereinafter referred to as “Guarantee Contract 3”). Fuhong Hanlin provided the maximum amount of joint and several liability guarantees for the debts of its holding subsidiary Hanlin Pharmaceuticals under the financing master contract signed with SPD Bank from April 9, 2024 to April 8, 2026. The principal amount of such debt shall not exceed the equivalent value of RMB 50 million. On April 1, 2024, the holding subsidiary Suqian Zhongwu Hospital Co., Ltd. (hereinafter referred to as “Suqian Zhongwu Hospital”) signed a “Comprehensive Credit Contract” with the Suqian Branch of China Minsheng Bank Co., Ltd. Suqian Zhongwu Hospital applied for a credit line with a principal amount not exceeding RMB 30 million from Minsheng Bank. The credit period ended from April 9, 2024 to April 8, 2025 (including the first and last two days). On April 9, 2024, the company and Minsheng Bank signed the “Maximum Guarantee Contract” (hereinafter referred to as “Guarantee Contract 4”). The company provided the maximum joint liability guarantee for the debts of Suqian Zhongwu Hospital under the above credit line. On April 9, 2024, Suqian Zhongwu Hospital signed a “Mortgage Contract” with the company, agreeing that Suqian Zhongwu Hospital will use land and real estate use/ownership rights (Suzhou (2023) Suqian City Real Estate Rights No. 0190911) as collateral for the aforementioned guarantee.

The 2022 Annual General Meeting of Shareholders of the Company deliberated and passed the bill on the Group's renewal and additional guarantee amounts, agreeing that the Group's renewal and additional guarantee amounts shall not exceed the equivalent of RMB 33.3 billion; at the same time, the company's management and/or its authorized persons are authorized to determine and adjust specific guarantee matters and sign relevant legal documents according to actual business needs within the above approved guarantee amounts. The above amount is valid from the date of adoption of the 2022 Annual General Meeting of Shareholders (that is, June 28, 2023) until the date the 2023 Annual General Meeting of Shareholders of the Company is held or any shareholders' meeting passes a resolution to withdraw or change the authorization described in this bill. The current guarantee is within the amount approved by the shareholders' meeting above.